Capricor Therapeutics to Hold Fourth Quarter 2014 Business Update Conference Call on March 18, 2015 at 4:30 p.m. EDT
LOS ANGELES, March 12, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (Nasdaq:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that company management will hold a conference call to discuss fourth quarter and full year 2014 business highlights at 4:30 p.m. EDT, March 18, 2015.
Access to the live webcast and teleconference is provided below:
- Webcast: http://public.viavid.com/index.php?id=113578
- Domestic dial-in: +1-877-407-4018
- International dial-in: +1-201-689-8471
Additionally, conference call details and a link to the replay of the webcast to be archived for 90 days will be available at http://capricor.com/news/events/.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (CAPR), a publicly traded biotechnology company, is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two leading product candidates: CAP-1002 and Cenderitide. The Company was formed through the November 2013 merger between Capricor, Inc., a privately held company whose mission is to improve the treatment of heart disease by commercializing cardiac stem cell therapies for patients, and Nile Therapeutics, Inc., a clinical-stage biopharmaceutical company developing innovative products for the treatment of cardiovascular diseases. For additional information visit www.capricor.com.
CONTACT: Corporate Contact
Capricor Therapeutics, Inc.
AJ Bergmann, Vice President of Finance
+1-310-358-3200
abergmann@capricor.com
Media Relations
Russo Partners
Christopher Hippolyte
+1-646-942-5634
chris.hippolyte@russopartnersllc.com
Tony Russo, Ph.D.
+1-212-845-4251
tony.russo@russopartnersllc.com
Investor Relations:
Russo Partners
Robert Flamm, Ph.D.
+1-212-845-4226
robert.flamm@russopartnersllc.com
Released March 12, 2015